MaxCyte Historical Cash Flow
| MXCT Stock | USD 3.52 0.14 4.14% |
Analysis of MaxCyte cash flow over time is an excellent tool to project MaxCyte future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 4 M or Begin Period Cash Flow of 13.9 M as it is a great indicator of MaxCyte ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining MaxCyte latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether MaxCyte is a good buy for the upcoming year.
MaxCyte |
About MaxCyte Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in MaxCyte balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which MaxCyte's non-liquid assets can be easily converted into cash.
MaxCyte Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by MaxCyte to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of MaxCyte operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Most accounts from MaxCyte's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into MaxCyte current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MaxCyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.At this time, MaxCyte's Investments are comparatively stable compared to the past year. Change To Operating Activities is likely to gain to about 8.6 M in 2024, despite the fact that Other Non Cash Items is likely to grow to (5.4 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Change To Liabilities | 4.0M | 687.5K | 790.6K | 751.1K | Change To Netincome | 8.6M | 11.9M | 13.7M | 14.4M |
MaxCyte cash flow statement Correlations
Click cells to compare fundamentals
MaxCyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
MaxCyte cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (1.9M) | (890.6K) | (1.4M) | (3.5M) | 697K | 731.9K | |
| Change In Cash | 4.0M | 3.5M | 29.0M | (36.7M) | 35.4M | 37.2M | |
| Stock Based Compensation | 1.8M | 2.5M | 8.0M | 11.8M | 14.0M | 14.7M | |
| Free Cash Flow | (10.1M) | (10.9M) | (14.5M) | (33.3M) | (25.4M) | (24.1M) | |
| Change In Working Capital | 1.6M | (858.2K) | (1.6M) | (3.2M) | 3.8M | 4.0M | |
| Begin Period Cash Flow | 11.2M | 15.2M | 18.8M | 47.8M | 11.1M | 13.9M | |
| Other Cashflows From Financing Activities | 5.1M | 401K | 3.6M | 2.9B | 1.9M | 1.8M | |
| Depreciation | 613.5K | 1.0M | 1.4M | 2.7M | 4.2M | 4.4M | |
| Other Non Cash Items | 76.9K | 101.6K | 57K | (2.5M) | (5.7M) | (5.4M) | |
| Capital Expenditures | 1.3M | 2.1M | 3.8M | 18.5M | 3.7M | 2.9M | |
| Total Cash From Operating Activities | (8.8M) | (8.8M) | (10.7M) | (14.8M) | (21.7M) | (20.6M) | |
| Change To Account Receivables | 1.6M | (1.8M) | (1.7M) | (6.7M) | 7.1M | 7.5M | |
| Net Income | (12.9M) | (11.8M) | (19.1M) | (23.6M) | (37.9M) | (36.0M) | |
| Total Cash From Financing Activities | 12.3M | 28.9M | 234.7M | 2.9M | 2.1M | 2.0M | |
| End Period Cash Flow | 15.2M | 18.8M | 47.8M | 11.1M | 46.5M | 48.8M | |
| Investments | 1.7M | (14.5M) | (191.2M) | (6.3M) | 32.0M | 33.6M | |
| Net Borrowings | (3.2K) | (152.2K) | (63.7K) | (5.0M) | (4.5M) | (4.3M) | |
| Total Cashflows From Investing Activities | 454.5K | (16.6M) | (195.0M) | (24.8M) | (22.3M) | (23.5M) | |
| Change To Operating Activities | (45.2K) | (198.2K) | (2.5M) | 7.2M | 8.2M | 8.6M | |
| Change To Netincome | 1.9M | 2.8M | 8.6M | 11.9M | 13.7M | 14.4M | |
| Change To Liabilities | 2.0M | 2.0M | 4.0M | 687.5K | 790.6K | 751.1K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.